Does the media prefer KRYS or ALNY?

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Krystal Biotech. MarketBeat recorded 7 mentions for Alnylam Pharmaceuticals and 2 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.25 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alnylam Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, BIIB or KRYS?

Biogen has higher revenue and earnings than Krystal Biotech. Biogen is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.31 $1.29B $5.65 39.17 Krystal Biotech $389.13M 24.84 $204.83M $7.98 40.93

Is BIIB or KRYS more profitable?

Krystal Biotech has a net margin of 54.82% compared to Biogen's net margin of 8.32%. Krystal Biotech's return on equity of 19.34% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Krystal Biotech 54.82% 19.34% 17.65%

Does the media refer more to BIIB or KRYS?

In the previous week, Biogen had 3 more articles in the media than Krystal Biotech. MarketBeat recorded 5 mentions for Biogen and 2 mentions for Krystal Biotech. Biogen's average media sentiment score of 1.02 beat Krystal Biotech's score of 0.25 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, KRYS or ROIV?

Krystal Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $389.13M 24.84 $204.83M $7.98 40.93 Roivant Sciences $8.26M 3,114.11 -$299.77M -$0.53 N/A

Does the media refer more to KRYS or ROIV?

In the previous week, Roivant Sciences had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 3 mentions for Roivant Sciences and 2 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.25 beat Roivant Sciences' score of -0.54 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

Which has stronger valuation and earnings, INSM or KRYS?

Krystal Biotech has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 39.17 -$1.28B -$4.11 N/A Krystal Biotech $389.13M 24.84 $204.83M $7.98 40.93

Is INSM or KRYS more profitable?

Krystal Biotech has a net margin of 54.82% compared to Insmed's net margin of -76.94%. Krystal Biotech's return on equity of 19.34% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Krystal Biotech 54.82% 19.34% 17.65%

Does the media prefer INSM or KRYS?

In the previous week, Insmed had 3 more articles in the media than Krystal Biotech. MarketBeat recorded 5 mentions for Insmed and 2 mentions for Krystal Biotech. Insmed's average media sentiment score of 0.59 beat Krystal Biotech's score of 0.25 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, KRYS or INCY?

Incyte has higher revenue and earnings than Krystal Biotech. Incyte is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $389.13M 24.84 $204.83M $7.98 40.93 Incyte $5.14B 4.60 $1.29B $7.85 14.87

Is KRYS or INCY more profitable?

Krystal Biotech has a net margin of 54.82% compared to Incyte's net margin of 27.71%. Incyte's return on equity of 29.93% beat Krystal Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Krystal Biotech 54.82% 19.34% 17.65% Incyte 27.71% 29.93% 22.88%

Does the media refer more to KRYS or INCY?

In the previous week, Incyte had 21 more articles in the media than Krystal Biotech. MarketBeat recorded 23 mentions for Incyte and 2 mentions for Krystal Biotech. Incyte's average media sentiment score of 0.62 beat Krystal Biotech's score of 0.25 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Incyte 7 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Krystal Biotech (KRYS) Competitors

$328.13 +2.82 (+0.87%)

As of 11:46 AM Eastern

Compare

KRYS vs. ALNY, BIIB, ROIV, INSM, and INCY

Should you buy Krystal Biotech stock or one of its competitors? Krystal Biotech's main competitors and comparable companies include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Roivant Sciences (ROIV), Insmed (INSM), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Krystal Biotech compare to Alnylam Pharmaceuticals?

Krystal Biotech (NASDAQ:KRYS) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Krystal Biotech has a net margin of 54.82% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Alnylam Pharmaceuticals has higher revenue and earnings than Krystal Biotech. Krystal Biotech is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	24.84	$204.83M	$7.98	40.93
Alnylam Pharmaceuticals	$3.71B	8.15	$313.75M	$5.38	42.06

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Krystal Biotech currently has a consensus price target of $377.20, suggesting a potential upside of 15.49%. Alnylam Pharmaceuticals has a consensus price target of $366.90, suggesting a potential upside of 62.13%. Given Alnylam Pharmaceuticals' higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Krystal Biotech. MarketBeat recorded 7 mentions for Alnylam Pharmaceuticals and 2 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.25 beat Alnylam Pharmaceuticals' score of 0.19 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alnylam Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Krystal Biotech has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

Summary

Krystal Biotech and Alnylam Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Biogen?

Biogen (NASDAQ:BIIB) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Biogen has higher revenue and earnings than Krystal Biotech. Biogen is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.31	$1.29B	$5.65	39.17
Krystal Biotech	$389.13M	24.84	$204.83M	$7.98	40.93

Biogen currently has a consensus target price of $230.14, suggesting a potential upside of 3.98%. Krystal Biotech has a consensus target price of $377.20, suggesting a potential upside of 15.49%. Given Krystal Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Krystal Biotech is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

87.9% of Biogen shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Krystal Biotech has a net margin of 54.82% compared to Biogen's net margin of 8.32%. Krystal Biotech's return on equity of 19.34% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Krystal Biotech	54.82%	19.34%	17.65%

In the previous week, Biogen had 3 more articles in the media than Krystal Biotech. MarketBeat recorded 5 mentions for Biogen and 2 mentions for Krystal Biotech. Biogen's average media sentiment score of 1.02 beat Krystal Biotech's score of 0.25 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biogen has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Summary

Krystal Biotech beats Biogen on 11 of the 17 factors compared between the two stocks.

How does Krystal Biotech compare to Roivant Sciences?

Krystal Biotech (NASDAQ:KRYS) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Krystal Biotech has a net margin of 54.82% compared to Roivant Sciences' net margin of -3,534.96%. Krystal Biotech's return on equity of 19.34% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

In the previous week, Roivant Sciences had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 3 mentions for Roivant Sciences and 2 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.25 beat Roivant Sciences' score of -0.54 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Krystal Biotech has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

Krystal Biotech currently has a consensus target price of $377.20, indicating a potential upside of 15.49%. Roivant Sciences has a consensus target price of $45.64, indicating a potential upside of 28.15%. Given Roivant Sciences' higher probable upside, analysts clearly believe Roivant Sciences is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Krystal Biotech has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	24.84	$204.83M	$7.98	40.93
Roivant Sciences	$8.26M	3,114.11	-$299.77M	-$0.53	N/A

Summary

Krystal Biotech beats Roivant Sciences on 12 of the 16 factors compared between the two stocks.

How does Krystal Biotech compare to Insmed?

Insmed (NASDAQ:INSM) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, Insmed had 3 more articles in the media than Krystal Biotech. MarketBeat recorded 5 mentions for Insmed and 2 mentions for Krystal Biotech. Insmed's average media sentiment score of 0.59 beat Krystal Biotech's score of 0.25 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Krystal Biotech has a net margin of 54.82% compared to Insmed's net margin of -76.94%. Krystal Biotech's return on equity of 19.34% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Krystal Biotech	54.82%	19.34%	17.65%

Krystal Biotech has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.17	-$1.28B	-$4.11	N/A
Krystal Biotech	$389.13M	24.84	$204.83M	$7.98	40.93

Insmed presently has a consensus target price of $200.57, suggesting a potential upside of 84.39%. Krystal Biotech has a consensus target price of $377.20, suggesting a potential upside of 15.49%. Given Insmed's higher possible upside, equities research analysts clearly believe Insmed is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

86.3% of Krystal Biotech shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Insmed has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Summary

Krystal Biotech beats Insmed on 8 of the 15 factors compared between the two stocks.

How does Krystal Biotech compare to Incyte?

Krystal Biotech (NASDAQ:KRYS) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Krystal Biotech currently has a consensus target price of $377.20, suggesting a potential upside of 15.49%. Incyte has a consensus target price of $126.15, suggesting a potential upside of 8.09%. Given Krystal Biotech's stronger consensus rating and higher probable upside, equities research analysts clearly believe Krystal Biotech is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Incyte	0 Sell rating(s)	12 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.56

Incyte has higher revenue and earnings than Krystal Biotech. Incyte is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	24.84	$204.83M	$7.98	40.93
Incyte	$5.14B	4.60	$1.29B	$7.85	14.87

In the previous week, Incyte had 21 more articles in the media than Krystal Biotech. MarketBeat recorded 23 mentions for Incyte and 2 mentions for Krystal Biotech. Incyte's average media sentiment score of 0.62 beat Krystal Biotech's score of 0.25 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Incyte	7 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 16.2% of Incyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Krystal Biotech has a net margin of 54.82% compared to Incyte's net margin of 27.71%. Incyte's return on equity of 29.93% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Incyte	27.71%	29.93%	22.88%

Krystal Biotech has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Incyte has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Summary

Incyte beats Krystal Biotech on 10 of the 17 factors compared between the two stocks.

Get Krystal Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRYS vs. The Competition

Export

Metric	Krystal Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.71B	$3.84B	$7.13B	$13.27B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	41.09	13.60	273.99	26.15
Price / Sales	24.84	1,296.00	608.65	93.06
Price / Cash	45.62	121.76	77.38	51.25
Price / Book	7.77	16.57	10.88	6.34
Net Income	$204.83M	-$22.67M	$3.50B	$361.18M
7 Day Performance	-5.56%	-2.20%	-1.62%	-1.17%
1 Month Performance	-11.55%	-10.00%	-5.90%	-3.40%
1 Year Performance	79.76%	22.34%	9.47%	3.28%

Krystal Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRYS Krystal Biotech	3.9817 of 5 stars	$328.13 +0.9%	$377.20 +15.0%	+81.1%	$9.72B	$389.13M	41.15	295
ALNY Alnylam Pharmaceuticals	3.9168 of 5 stars	$255.36 -0.2%	$367.20 +43.8%	-49.8%	$34.25B	$3.71B	47.46	2,500	Analyst Forecast
BIIB Biogen	2.7483 of 5 stars	$228.69 +0.5%	$230.14 +0.6%	+44.5%	$33.63B	$9.89B	40.48	7,500	Positive News
ROIV Roivant Sciences	2.6351 of 5 stars	$36.98 +3.3%	$45.64 +23.4%	+125.4%	$25.86B	$8.26M	N/A	721
INSM Insmed	3.6153 of 5 stars	$117.67 -0.1%	$201.87 +71.6%	-26.3%	$25.73B	$606.42M	N/A	1,664	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRYS) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Krystal Biotech (KRYS) Competitors

KRYS vs. ALNY, BIIB, ROIV, INSM, and INCY

How does Krystal Biotech compare to Alnylam Pharmaceuticals?

Summary

How does Krystal Biotech compare to Biogen?

Summary

How does Krystal Biotech compare to Roivant Sciences?

Summary

How does Krystal Biotech compare to Insmed?

Summary

How does Krystal Biotech compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Krystal Biotech (KRYS) Competitors

KRYS vs. ALNY, BIIB, ROIV, INSM, and INCY

How does Krystal Biotech compare to Alnylam Pharmaceuticals?

Is KRYS or ALNY more profitable?

Which has preferable valuation and earnings, KRYS or ALNY?

Do institutionals and insiders have more ownership in KRYS or ALNY?

Do analysts recommend KRYS or ALNY?

Does the media prefer KRYS or ALNY?

Which has more risk & volatility, KRYS or ALNY?

Summary

How does Krystal Biotech compare to Biogen?

Which has better valuation and earnings, BIIB or KRYS?

Do analysts recommend BIIB or KRYS?

Do insiders & institutionals hold more shares of BIIB or KRYS?

Is BIIB or KRYS more profitable?

Does the media refer more to BIIB or KRYS?

Which has more risk & volatility, BIIB or KRYS?

Summary

How does Krystal Biotech compare to Roivant Sciences?

Is KRYS or ROIV more profitable?

Does the media refer more to KRYS or ROIV?

Do insiders & institutionals believe in KRYS or ROIV?

Which has more volatility and risk, KRYS or ROIV?

Do analysts prefer KRYS or ROIV?

Which has stronger valuation & earnings, KRYS or ROIV?

Summary

How does Krystal Biotech compare to Insmed?

Does the media prefer INSM or KRYS?

Is INSM or KRYS more profitable?

Which has stronger valuation and earnings, INSM or KRYS?

Do analysts rate INSM or KRYS?

Do insiders and institutionals hold more shares of INSM or KRYS?

Which has more risk & volatility, INSM or KRYS?

Summary

How does Krystal Biotech compare to Incyte?

Do analysts recommend KRYS or INCY?

Which has preferable valuation and earnings, KRYS or INCY?

Does the media refer more to KRYS or INCY?

Do institutionals and insiders hold more shares of KRYS or INCY?

Is KRYS or INCY more profitable?

Which has more volatility & risk, KRYS or INCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRYS vs. The Competition

Krystal Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools